notes of interet: while elto trial is paused t
Post# of 30028
while elto trial is paused the company is looking at business development opportunities with the asset
they're looking to uplist in 4Q
18-24 months for ESS to market, same with PRV sale
$10mill to get first indication approved
not tons of suitors for ESS because of it's nature. They would sell it if the right bidder/bid came along. regen medicine space is exciting option
ESS manufacturing is key, 12 months top 2 data. FDa more comfortable with Pediatric space, military/government wants work done on adults